摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3β-methoxy-17,17-ethylenedioxyandrost-5-en-7-one | 357923-20-7

中文名称
——
中文别名
——
英文名称
3β-methoxy-17,17-ethylenedioxyandrost-5-en-7-one
英文别名
(3'S,8'R,9'S,10'R,13'S,14'S)-3'-methoxy-10',13'-dimethylspiro[1,3-dioxolane-2,17'-2,3,4,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-7'-one
3β-methoxy-17,17-ethylenedioxyandrost-5-en-7-one化学式
CAS
357923-20-7
化学式
C22H32O4
mdl
——
分子量
360.494
InChiKey
KBCQXYMRDJTLES-POBLZQCHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    26
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    44.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates
    摘要:
    The 7-oxo derivative of dehydroepiandrosterone is more active than the parent steroid and is devoid of adverse side effects in rats, monkeys and humans. In anticipation of possible therapeutic use we have sought more active, longer lasting forms of 7-oxo- and 7 beta -hydroxydehydroepiandrosterones. The 7-oxo- and 7-hydroxy steroids have been converted to glucuronides, ethers and carbonate esters. The syntheses of these compounds are described and their ability to induce the formation of liver thermogenic enzymes when fed to rats is reported. Some of the new derivatives were found to be somewhat more effective than the equimolar amounts of 7-oxo-DHEA with which they were compared in each experiment. (C) 2001 Elsevier Science Inc. All rights reserved.
    DOI:
    10.1016/s0039-128x(00)00234-8
  • 作为产物:
    参考文献:
    名称:
    Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates
    摘要:
    The 7-oxo derivative of dehydroepiandrosterone is more active than the parent steroid and is devoid of adverse side effects in rats, monkeys and humans. In anticipation of possible therapeutic use we have sought more active, longer lasting forms of 7-oxo- and 7 beta -hydroxydehydroepiandrosterones. The 7-oxo- and 7-hydroxy steroids have been converted to glucuronides, ethers and carbonate esters. The syntheses of these compounds are described and their ability to induce the formation of liver thermogenic enzymes when fed to rats is reported. Some of the new derivatives were found to be somewhat more effective than the equimolar amounts of 7-oxo-DHEA with which they were compared in each experiment. (C) 2001 Elsevier Science Inc. All rights reserved.
    DOI:
    10.1016/s0039-128x(00)00234-8
点击查看最新优质反应信息

文献信息

  • Blood cell deficiency treatment method
    申请人:——
    公开号:US20030083231A1
    公开(公告)日:2003-05-01
    The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.
    该发明涉及使用化合物治疗多种疾病,如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。
  • Compositions and treatment methods
    申请人:Ahlem N. Clarence
    公开号:US20060079492A1
    公开(公告)日:2006-04-13
    The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.
    本发明涉及使用化合物治疗多种疾病,例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄甾烷可用于治疗方法。
  • COMPOSITIONS AND TREATMENT METHODS-2
    申请人:Frincke James M.
    公开号:US20100222425A1
    公开(公告)日:2010-09-02
    The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.
    本发明涉及使用化合物治疗多种疾病,例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可以在本发明中使用的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄烷。这些化合物可以用于治疗方法中。
  • 15-THIA STEROID COMPOUNDS AND COMPOSITIONS
    申请人:Frincke James M.
    公开号:US20110218162A1
    公开(公告)日:2011-09-08
    The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.
    本发明涉及使用化合物治疗多种疾病,例如血小板减少症、中性粒细胞减少症或放射治疗的延迟效应。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄烷,可用于治疗方法。
  • Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
    申请人:Hollis-Eden Pharmaceuticals Inc.
    公开号:EP2135611A1
    公开(公告)日:2009-12-23
    The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate.
    本发明涉及使用化合物治疗多种疾病,如血小板减少症、中性粒细胞减少症或放射治疗的延迟效应。可用于本发明的化合物包括 2,3,4-三羟基-1-O-(7,17-二氧代雄甾烷-5-烯-3β-基)-β-D-吡喃葡萄糖苷酸甲酯。
查看更多